| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 05/26/2011 | US20110124731 Treatment Of Neurodegenerative Diseases And Cancer Of The Brain Using Histone Deacetylase Inhibitors |
| 05/26/2011 | US20110124728 Dha enrichment process |
| 05/26/2011 | US20110124672 Thienyl Compounds |
| 05/26/2011 | US20110124607 Composition for regulation cellular senescence comprising lysophosphatidic acid and inhibitor of adenylyl cyclase as active ingredients |
| 05/26/2011 | US20110124580 Regulation of lung tissue by hedgehog-like polypeptides, and formulations and uses related thereto |
| 05/26/2011 | US20110124567 Therapeutic compounds and methods |
| 05/26/2011 | US20110123653 Compositions and methods for optimizing exercise recovery |
| 05/26/2011 | US20110123649 Herbal extract composition |
| 05/26/2011 | US20110123638 Method for the intradermal delivery of substances |
| 05/26/2011 | US20110123625 Compositions of Less Immunogenic and Long-Circulating Protein-Lipid Complexes |
| 05/26/2011 | US20110123604 Absorbent polymeric compositions with varying counterion content and their methods of preparation and use |
| 05/26/2011 | US20110123601 Biofunctionalized phospholipid-capped mesoporous silica nanoshuttles for targeted drug delivery |
| 05/26/2011 | US20110123599 Aroma therapy patch |
| 05/26/2011 | US20110123592 Biomaterials |
| 05/26/2011 | US20110123572 Activated fibroblasts for treating tissue and/or organ damage |
| 05/26/2011 | US20110123571 Use of bacterium for manufacture of a vaccine |
| 05/26/2011 | US20110123526 Methods and compositions for preventing adhesion |
| 05/26/2011 | US20110123520 Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
| 05/26/2011 | US20110123512 Method of regulating the heat shock response |
| 05/26/2011 | US20110123495 Derivatives of pyridone and use thereof |
| 05/26/2011 | US20110123488 Method of Treatment for Cancers Associated with Elevated HER2 Levels |
| 05/26/2011 | US20110123481 Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications |
| 05/26/2011 | US20110123452 Metal oligomers and polymers and their use in biology and medicine |
| 05/26/2011 | US20110123450 Macrocyclic cyanine and indocyanine bioconjugates provide improved biomedical application |
| 05/26/2011 | US20110123438 Universal anchor peptide for nanoparticles |
| 05/26/2011 | DE102010039912A1 Use of ginger in feed in a specified daily amount to reduce cortisol levels in the blood of the horse, e.g. for the treatment of equine Cushing's syndrome |
| 05/26/2011 | CA2781332A1 System for increasing gene expression and vector comprising the system |
| 05/26/2011 | CA2777719A1 Apremilast for the treatment of sarcoidosis |
| 05/25/2011 | EP2325205A2 Crystals of whole antibodies and fragments thereof and methods for making and using them |
| 05/25/2011 | EP2325203A2 Cadherin materials and methods |
| 05/25/2011 | EP2325181A1 Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient |
| 05/25/2011 | EP2325179A1 Glycosidase ihhibitors and preparation thereof |
| 05/25/2011 | EP2324856A1 Single-stranded oligodeoxynucleotide mutational vectors |
| 05/25/2011 | EP2324852A1 Therapeutic or prophylactic agent for generalized pain syndrome |
| 05/25/2011 | EP2324843A1 Use of TNF-alpha inhibitors for treating nerve root injury |
| 05/25/2011 | EP2324839A1 Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
| 05/25/2011 | EP2324836A1 Antitumor agent containing 4-[[3,5-bis(trimethylsilyl)benzoyl]amino¨benzoic acid |
| 05/25/2011 | EP2324834A2 Methods of Increasing Endogenous Erythropoietin (EPO) |
| 05/25/2011 | EP2324830A1 Process for the preparation of a monocyclic azole derivative that inhibits the interaction of ligands with rage |
| 05/25/2011 | EP2324827A1 Therapeutic agent for anca-related vasculitis |
| 05/25/2011 | EP2324826A1 Hydrophilic amino acid-containing preparation having improved taste |
| 05/25/2011 | EP2324825A1 Aryl ureas with angiogenesis inhibiting activity |
| 05/25/2011 | EP2324812A2 Composition exhibiting enhanced formulation stability and delivery of topical active ingredients |
| 05/25/2011 | EP1534296B1 Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure |
| 05/25/2011 | EP1381384B1 COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNFalpha |
| 05/25/2011 | EP1374902B1 Anti-AILIM antibodies for the treatment of Crohn's disease |
| 05/25/2011 | EP1335726B1 Modified prodrug forms of ap |
| 05/25/2011 | EP1317454B1 Caspase inhibitors and uses thereof |
| 05/25/2011 | EP1263463B1 Use of an antibody or an immunotoxin that selectively binds to cd123 to impair hematologic cancer progenitor cells |
| 05/25/2011 | CN1871347B Method and kit for detecting proliferative diseases causing sclerosis, preventive and/or remedy for proliferative diseases causing sclerosis and method and kit for identifying substance efficacious in |
| 05/25/2011 | CN1660278B Compound injection of Chinese angelica root and chuanxiong rhizome and preparation method |
| 05/25/2011 | CN1578663B Inhibitors of histone deacetylase |
| 05/25/2011 | CN1285752B Processes of making north american ginseng fractions, products containing them, and use as immunomodulators |
| 05/25/2011 | CN102076682A Five-membered ring compound |
| 05/25/2011 | CN102076672A Novel five-membered ring compound |
| 05/25/2011 | CN102076671A Triazole derivative or salt thereof |
| 05/25/2011 | CN102076660A Sulfonamide compound or salt thereof |
| 05/25/2011 | CN102076351A Pharmaceutical agent for promoting functional regeneration of damaged tissue |
| 05/25/2011 | CN102076350A Agent for recruitment of bone-marrow-derived pluripotent stem cell into peripheral circulation |
| 05/25/2011 | CN102076337A Use of dronedarone for preparing a medicament for the treatment of patients with arrhythmia and having an increase of creatinine level due to dronedarone administration |
| 05/25/2011 | CN102070631A Quaternary ammonium salt of penehyclidine optical isomer, medicinal composition and medical application thereof |
| 05/25/2011 | CN102070605A Imatinib mesylate polymorph and pharmaceutical composition |
| 05/25/2011 | CN102070595A Substituted benzoxanthone type compound and application thereof |
| 05/25/2011 | CN102068701A Application of cleavable polyethylene glycol (PEG) lipid derivative to preparation |
| 05/25/2011 | CN102068603A Chinese medicament for treating lupus erythematosus |
| 05/25/2011 | CN102068566A Quality control method for Yinchen Wudan pills for treating damp-heat jaundice |
| 05/25/2011 | CN102068549A Quality control method for Chinese medicinal preparation heat clearing and blood cooling pills |
| 05/25/2011 | CN102068481A Preparation and application of low-toxicity effective fraction for suppressing angiogenesis in cowherb seed |
| 05/25/2011 | CN102068421A Application of alkannin in preparation of pyruvate kinase inhibitor |
| 05/25/2011 | CN101579455B Traditional Chinese medicine preparation for treating consumptive disease |
| 05/25/2011 | CN101560214B 4-amino-6-phenyl-pyrrolo[2, 3-d]pyrimidine derivatives |
| 05/25/2011 | CN101475526B Carboxylic acid derivatives inhibiting the binding of integrins to receptors thereof |
| 05/25/2011 | CN101444629B Non-injection gene therapy medicine and medicine box thereof |
| 05/25/2011 | CN101420946B Tamsulosin-containing percutaneous absorption type preparation |
| 05/25/2011 | CN101361972B Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
| 05/25/2011 | CN101186870B Functionality solomonseal fruit wine and producing method thereof |
| 05/25/2011 | CN101077104B Gynostemma pentaphyllum tea |
| 05/24/2011 | US7947713 Tripeptidyl peptidase inhibitors |
| 05/24/2011 | US7947684 anticoagulants; immunomoderators; antiinflammatory agents |
| 05/24/2011 | US7947498 Embryonic stem cells and neural progenitor cells derived therefrom |
| 05/24/2011 | US7947472 An expression vector comprising a sequence of human DNA encoding vascular endothelial growth factor-D (VEGF-D) or a fragment having the biological activity of VEGF-D, inserted into a mammalian expression vector |
| 05/24/2011 | US7947462 Methods for identifying Kremen polypeptide binding partners |
| 05/24/2011 | US7947312 Method of preparation and composition of a water soluble extract of the bioactive component of the plant species Uncaria for enhancing immune, anti-inflammatory, anti-tumor and DNA repair processes of warm blooded animals |
| 05/24/2011 | US7947299 Compositions and techniques for localized therapy |
| 05/24/2011 | US7947287 Peptides for the treatment of cancer associated with the human papilloma virus (HPV) and other epithelial tumors |
| 05/24/2011 | US7947272 Using mixture comprising inhibitors of CD4, CD25 and interleukin induction as tool in reducing immune response to tissue graft; preventing transplant rejection |
| 05/24/2011 | CA2531239C Pharmaceutical formulations for intranasal administration of protein comprising a chitosan or a derivative thereof |
| 05/24/2011 | CA2508194C Use of ibudilast as a phosphodiesterase 10a inhibitor |
| 05/24/2011 | CA2490888C Diaminopyrimidinecarboxamide derivative |
| 05/24/2011 | CA2490239C Substituted 2,4-dihydro-pyrrolo (3, 4-b) -quinolin-9-one derivatives useful as phosphodiesterase inhibitors |
| 05/24/2011 | CA2479737C Nanoparticulate compositions of map kinase inhibitors |
| 05/24/2011 | CA2477601C 5-phenylthiazole derivatives and use as pi3 kinase inhibitors |
| 05/24/2011 | CA2472821C Process for producing fused imidazole compound, and reformatsky reagent in stable form and process for producing the same |
| 05/24/2011 | CA2471642C 6-fluorobicyclo[3.1.0]hexane derivatives |
| 05/24/2011 | CA2468719C Prevention and treatment of androgen-deprivation induced osteoporosis |
| 05/24/2011 | CA2467552C Nicotin-or isonicotin benzothiazole derivatives |
| 05/24/2011 | CA2464358C Alkyl ether derivatives or their salts |
| 05/24/2011 | CA2463626C Piperidine- and piperazineacetamines as 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| 05/24/2011 | CA2450467C Methods for modulating bladder function |
| 05/24/2011 | CA2443952C Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors |